Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Clin Cancer Res. 2015 Mar 4;21(11):2580–2590. doi: 10.1158/1078-0432.CCR-14-2191

Figure 1. YAP and EGFR are overexpressed in EC tumor tissues and associated with therapy resistance.

Figure 1

A. Expression of YAP and EGFR were determined by immunoblotting in Barrett's and EAC cell lines as described in Materials & Methods. B. Expression of YAP and EGFR were determined by immunohistochemistry using antibodies against YAP1 and EGFR in EAC TMA tissues. Representative YAP1 and EGFR staining are shown in normal and EAC tissues. C. Expression of YAP and EGFR were determined by immunohistochemistry in sensitive EAC tumor tissues (P0/pCR), relative sensitive tumor tissues (P1) and resistant tumor tissues (P2). Both EGFR and YAP highly expressed in majority of P2 tissues. D. Expression of EGFR significantly correlated the poor survival of EAC patients. Cox Regression for OS analysis; p<0.01.